{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:04:22Z","timestamp":1782299062739,"version":"3.54.5"},"reference-count":16,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Vaccine Surveillance Reference group","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}]},{"name":"COVID-19 Immunity Task Force","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}]},{"name":"Canada Research Chair on Systemic Autoimmune Rheumatic Diseases","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}]},{"name":"Department of Medicine, University of Toronto","award":["2122-HQ-000070"],"award-info":[{"award-number":["2122-HQ-000070"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Objective: SARS-CoV-2 remains the third most common cause of death in North America. We studied the effects of methotrexate and tumor necrosis factor inhibitor (TNFi) on neutralization responses after COVID-19 vaccination in immune-mediated inflammatory disease (IMID). Methods: Prospective data and sera of adults with inflammatory bowel disease (IBD), rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA), and systemic lupus (SLE) were collected at six academic centers in Alberta, Manitoba, Ontario, and Quebec between 2022 and 2023. Sera from two time points were evaluated for each subject. Neutralization studies were divided between five laboratories, and each lab\u2019s results were analyzed separately using multivariate generalized logit models (ordinal outcomes: absent, low, medium, and high neutralization). Odds ratios (ORs) for the effects of methotrexate and TNFi were adjusted for demographics, IMID, other biologics and immunosuppressives, prednisone, COVID-19 vaccinations (number\/type), and infections in the 6 months prior to sampling. The adjusted ORs for methotrexate and TNFi were then pooled in random-effects meta-analyses (separately for the ancestral strains and the Omicron BA1 and BA5 strains). Results: Of 479 individuals (958 samples), 292 (61%) were IBD, 141 (29.4%) were RA, and the remainder were PsA, SpA, and SLE. The mean age was 57 (62.2% female). For both the individual labs and the meta-analyses, the adjusted ORs suggested independent negative effects of TNFi and methotrexate on neutralization. The meta-analysis adjusted ORs for TNFi were 0.56 (95% confidence interval (CI) 0.39, 0.81) for the ancestral strain and 0.56 (95% CI 0.39, 0.81) for BA5. The meta-analysis adjusted OR for methotrexate was 0.39 (95% CI 0.19, 0.76) for BA1. Conclusions: SARS-CoV-2 neutralization in vaccinated IMID was diminished independently by TNFi and methotrexate. As SARS-CoV-2 circulation continues, ongoing vigilance regarding optimized vaccination is required.<\/jats:p>","DOI":"10.3390\/vaccines12091061","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:51:43Z","timestamp":1726620703000},"page":"1061","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-3268","authenticated-orcid":false,"given":"Carol A","family":"Hitchon","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-2957","authenticated-orcid":false,"given":"Dawn M. E.","family":"Bowdish","sequence":"additional","affiliation":[{"name":"McMaster Immunology Research Centre, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2481-5821","authenticated-orcid":false,"given":"Gilles","family":"Boire","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, Universit\u00e9 de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7278-2596","authenticated-orcid":false,"given":"Paul R.","family":"Fortin","sequence":"additional","affiliation":[{"name":"Centre de Recherche ARThrite\u2014UL, Division of Rheumatology, Department of Medicine, CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"},{"name":"Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Flamand","sequence":"additional","affiliation":[{"name":"Axe Maladies Infectieuses et Immunitaires, Centre de Recherche du CHU de Qu\u00e9bec, Universit\u00e9 Laval, Qu\u00e9bec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute and Krembil Research Institute, University Health Network, Toronto, ON M5T 2S8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya M.","family":"Dayam","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1X5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claude","family":"Gingras","sequence":"additional","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health, Toronto, ON M5G 1X5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Card","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, MB R3T 2N2, Canada"},{"name":"JC Wilt Infectious Diseases Research Centre, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3T 2N2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Colmegna","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H3A 0E9, Canada"},{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Larch\u00e9","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-0556","authenticated-orcid":false,"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB T2N 1N4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6435-8140","authenticated-orcid":false,"given":"Luck","family":"Lukusa","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5501-0017","authenticated-orcid":false,"given":"Jennifer L.F.","family":"Lee","sequence":"additional","affiliation":[{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, McGill University, Montreal, QC H3A 0E9, Canada"},{"name":"The Research Institute of the McGill University Health Centre, McGill University, Montreal, QC H3A 0E9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SUCCEED Investigative Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,17]]},"reference":[{"key":"ref_1","unstructured":"Statistic Canada (2024, July 29). Leading Causes of Death, Total Population, by Age Group. Available online: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1310039401."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e159721","DOI":"10.1172\/jci.insight.159721","article-title":"Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseases","volume":"7","author":"Dayam","year":"2022","journal-title":"JCI Insight"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41577-022-00813-1","article-title":"Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection","volume":"23","author":"Zhang","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e003400","DOI":"10.1136\/rmdopen-2023-003400","article-title":"COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): Safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series","volume":"9","author":"Colmegna","year":"2023","journal-title":"RMD Open"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"01835","DOI":"10.1016\/j.xpro.2022.101835","article-title":"A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay","volume":"3","author":"Sievers","year":"2022","journal-title":"STAR Protoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e071397","DOI":"10.1136\/bmjopen-2022-071397","article-title":"Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: A single-centre prospective cohort study","volume":"13","author":"Hitchon","year":"2023","journal-title":"BMJ Open"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zheng, Y.Q., Li, H.J., Chen, L., and Lin, S.P. (2022). Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-22839-0"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Morales-N\u00fa\u00f1ez, J.J., Mu\u00f1oz-Valle, J.F., Torres-Hern\u00e1ndez, P.C., and Hern\u00e1ndez-Bello, J. (2021). Overview of Neutralizing Antibodies and Their Potential in COVID-19. Vaccines, 9.","DOI":"10.3390\/vaccines9121376"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s10067-024-07013-3","article-title":"Effect of methotrexate hold on COVID-19 vaccine response in the patients with autoimmune inflammatory disorders: A systematic review and meta-analysis","volume":"43","author":"Imran","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.gastro.2021.10.029","article-title":"Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with Anti-TNF\u03b1","volume":"162","author":"Zittan","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"105464","DOI":"10.1016\/j.jbspin.2022.105464","article-title":"Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis","volume":"90","author":"Saad","year":"2023","journal-title":"Jt. Bone Spine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41467-022-28517-z","article-title":"Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab","volume":"13","author":"Lin","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Garner-Spitzer, E., Wagner, A., Gudipati, V., Schoetta, A.M., Orola-Taus, M., Kundi, M., Kunert, R., Mayrhofer, P., Huppa, J.B., and Stockinger, H. (2023). Lower magnitude and faster waning of antibody responses to SARS-CoV-2 vaccination in anti-TNF-\u03b1-treated IBD patients are linked to lack of activation and expansion of cTfh1 cells and impaired B memory cell formation. EBioMedicine, 96.","DOI":"10.1016\/j.ebiom.2023.104788"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"931","DOI":"10.15585\/mmwr.mm7129e1","article-title":"Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2\/BA.2.12.1 Sublineages Predominated\u2014VISION Network, 10 States, December 2021\u2013June 2022","volume":"71","author":"Levy","year":"2022","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e28156","DOI":"10.1002\/jmv.28156","article-title":"Prevalence and factors related to COVID-19 vaccine hesitancy and unwillingness in Canada: A systematic review and meta-analysis","volume":"95","author":"Cenat","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"SI68","DOI":"10.1093\/rheumatology\/keab432","article-title":"Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases","volume":"60","author":"Felten","year":"2021","journal-title":"Rheumatology"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1061\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:58:09Z","timestamp":1760111889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,17]]},"references-count":16,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12091061"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12091061","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,17]]}}}